Please contact us for more information or to learn if you are eligible to participate.
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.
Sriramanchandra M. Badiga, MD
Edgar Lopez Pacheco
Eli Lilly and Company/USA
Type of Trial